Jennifer Erich
Primary Care · Pleasant Prairie, WINPI 1407555063
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 24.6% of the total. 2025 is the largest year on record at $728, 4.3 times the $168 reported in 2023.
Across 54 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$290
- AbbVie$209
- Exact Sciences$142
- Astellas Pharma US Inc$107
- Lilly USA, LLC$82
- Dexcom, Inc.$80
- plus $267 from 7 others
What the payments were for
- Food & beverage$1,176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $290 |
| AbbVie | 9 | $209 |
| Exact Sciences | 6 | $142 |
| Astellas Pharma US Inc | 5 | $107 |
| Lilly USA, LLC | 5 | $82 |
| Dexcom, Inc. | 4 | $80 |
| AstraZeneca | 4 | $74 |
| Abbott | 3 | $67 |
| Corium, LLC | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| GSK | 1 | $18 |
How this compares
$1,176 in reported general payments places this provider in the 80th percentile of 52 primary care providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $28,361 |
| MounjaroTirzepatide | 18 | $25,424 |
| JardianceEmpagliflozin | 32 | $25,279 |
| OzempicSemaglutide | 12 | $15,954 |
| MyrbetriqMirabegron | 14 | $7,079 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $6,537 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,506 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $1,839 |
| Oxybutynin Chloride | 13 | $1,679 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $1,626 |
| Gabapentin | 90 | $1,434 |
| Levothyroxine Sodium | 122 | $1,176 |
| Omeprazole | 98 | $1,127 |
| Pantoprazole Sodium | 87 | $1,117 |
| Atorvastatin Calcium | 168 | $1,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $22 | $28,36134 claims |
| Lilly USA, LLCMounjaro | $82 | $25,42418 claims |
| Novo NordiskOzempic | $290 | $15,95412 claims |
| Astellas Pharma US IncMyrbetriq | $107 | $7,07914 claims |
| GSKIncruse Ellipta | $18 | $4,50613 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $29 | $44817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 52 primary care providers in Wisconsin.
Other primary care in Pleasant Prairie
- Michael PotnekMilwaukee$71K
- Jennifer KrallWausau$4K
- Stephanie BrownKenosha$3K
- Emily OrganBrookfield$2K
- Heather MeeusenPlymouth$2K
- Kelly StoneMilwaukee$2K
- Courtney LammMilwaukee$2K
- Mary WiseMilwaukee$2K
- Dayna OsborneJanesville$1K
- Pauline HaririePewaukee$750
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.